# Mazdutide

Mazdutide has 37 registered human trials. It is marketed for 3 different uses.

**In short**

- 37 registered human trials exist for Mazdutide.
- Mazdutide is not FDA-approved for any use.
- What has actually been studied: obesity, overweight and obesity, overweight/ obesity.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Weight loss
- Blood sugar control
- Metabolic health

## What has actually been tested

- Obesity
- Overweight and Obesity
- Overweight/ Obesity
- Weight Control
- Severe Obesity
- Obesity Or Overweight
- Healthy
- Type 2 Diabetes Mellitus (T2DM)
- Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
- Overweight/Obesity
- Sleep Apnea
- Obstructive
- Metabolic Dysfunction-Associated Steatohepatitis
- Hepatic Steatosis
- Living Liver Donors
- Alcohol Use Disorder
- Adolescents With Obesity
- Overweight
- Type 2 Diabetes
- Dementia, Mild
- Mild Cognitive Impairment
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Diabetes Mellitus, Type 2
- Hypertensive
- Overweight Subjects
- Obese Subjects
- Obesity & Overweight
- Coronary Heart Disease
- Polycystic Ovary Syndrome
- Adolescents With Obesity or Overweight With Weight-Related Comorbidities
- Overweight or Obesity
- Prediabetes
- Impaired Fasting Glucose
- Impaired Glucose Tolerance (Prediabetes)
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Heart Failure With Mildly Reduced Ejection Fraction
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Renal Impairment

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT06124807](https://clinicaltrials.gov/study/NCT06124807) | A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity, Overweight and Obesity | Phase 2 | COMPLETED | 179 |
| [NCT04904913](https://clinicaltrials.gov/study/NCT04904913) | A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects | Overweight/ Obesity | Phase 2 | COMPLETED | 328 |
| [NCT07517042](https://clinicaltrials.gov/study/NCT07517042) | ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management | Obesity, Weight Control | Not phased | RECRUITING | 420 |
| [NCT07135141](https://clinicaltrials.gov/study/NCT07135141) | Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity | Severe Obesity | Not phased | NOT_YET_RECRUITING | 256 |
| [NCT05607680](https://clinicaltrials.gov/study/NCT05607680) | A Study of IBI362 in Participants With Obesity or Overweight | Obesity Or Overweight | Phase 3 | COMPLETED | 610 |
| [NCT02972645](https://clinicaltrials.gov/study/NCT02972645) | A Study of LY3305677 in Healthy Participants | Healthy | Phase 1 | COMPLETED | 66 |
| [NCT07713992](https://clinicaltrials.gov/study/NCT07713992) | Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide | Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus | Not phased | NOT_YET_RECRUITING | 72 |
| [NCT04773977](https://clinicaltrials.gov/study/NCT04773977) | Clinical Study of IBI362 in Healthy Chinese Male Subjects | Overweight/Obesity | Phase 1 | COMPLETED | 24 |
| [NCT06931028](https://clinicaltrials.gov/study/NCT06931028) | A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | Sleep Apnea, Obstructive | Phase 3 | RECRUITING | 260 |
| [NCT07718126](https://clinicaltrials.gov/study/NCT07718126) | Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis | Phase 3 | NOT_YET_RECRUITING | 60 |
| [NCT06817356](https://clinicaltrials.gov/study/NCT06817356) | A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Alcohol Use Disorder | Phase 2 | COMPLETED | 308 |
| [NCT07000955](https://clinicaltrials.gov/study/NCT07000955) | Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | Phase 2 | ACTIVE_NOT_RECRUITING | 98 |
| [NCT06536023](https://clinicaltrials.gov/study/NCT06536023) | This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity | Adolescents With Obesity | Phase 1 | COMPLETED | 36 |
| [NCT06143956](https://clinicaltrials.gov/study/NCT06143956) | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Obesity, Overweight | Phase 2 | RECRUITING | 1481 |
| [NCT07417306](https://clinicaltrials.gov/study/NCT07417306) | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | Type 2 Diabetes | Phase 3 | NOT_YET_RECRUITING | 912 |
| [NCT07083154](https://clinicaltrials.gov/study/NCT07083154) | GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) | Dementia, Mild, Mild Cognitive Impairment | Phase 3 | RECRUITING | 420 |
| [NCT06937749](https://clinicaltrials.gov/study/NCT06937749) | A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | RECRUITING | 165 |
| [NCT05623839](https://clinicaltrials.gov/study/NCT05623839) | A Study of LY3305677 in Participants With Obesity Or Overweight | Overweight, Obesity | Phase 1 | COMPLETED | 32 |
| [NCT05606913](https://clinicaltrials.gov/study/NCT05606913) | A Study of IBI362 in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 3 | COMPLETED | 731 |
| [NCT03928379](https://clinicaltrials.gov/study/NCT03928379) | A Study of LY3305677 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 24 |
| [NCT07469800](https://clinicaltrials.gov/study/NCT07469800) | Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Overweight, Obesity | Phase 3 | RECRUITING | 336 |
| [NCT05815680](https://clinicaltrials.gov/study/NCT05815680) | A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects | Overweight Subjects, Obese Subjects | Phase 1 | COMPLETED | 48 |
| [NCT07633639](https://clinicaltrials.gov/study/NCT07633639) | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Obesity | Not phased | RECRUITING | 200 |
| [NCT07657676](https://clinicaltrials.gov/study/NCT07657676) | Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity | Obesity & Overweight, Coronary Heart Disease | Phase 4 | NOT_YET_RECRUITING | 116 |
| [NCT06164873](https://clinicaltrials.gov/study/NCT06164873) | A Study of IBI362 9 mg in Chinese Adults With Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 462 |
| [NCT06519656](https://clinicaltrials.gov/study/NCT06519656) | Efficacy of Mazdutide for Treating PCOS | Polycystic Ovary Syndrome | Phase 2 | RECRUITING | 50 |
| [NCT07255209](https://clinicaltrials.gov/study/NCT07255209) | A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | Adolescents With Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | RECRUITING | 180 |
| [NCT04440345](https://clinicaltrials.gov/study/NCT04440345) | Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects | Overweight or Obesity | Phase 2 | COMPLETED | 60 |
| [NCT07654062](https://clinicaltrials.gov/study/NCT07654062) | Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) | Prediabetes, Impaired Fasting Glucose | Phase 4 | NOT_YET_RECRUITING | 150 |
| [NCT05628311](https://clinicaltrials.gov/study/NCT05628311) | A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Type 2 Diabetes | Phase 3 | COMPLETED | 319 |
| [NCT06862908](https://clinicaltrials.gov/study/NCT06862908) | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | RECRUITING | 141 |
| [NCT06184568](https://clinicaltrials.gov/study/NCT06184568) | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Type 2 Diabetes, Obesity | Phase 3 | COMPLETED | 349 |
| [NCT04466904](https://clinicaltrials.gov/study/NCT04466904) | Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM | Type 2 Diabetes | Phase 2 | COMPLETED | 42 |
| [NCT06884293](https://clinicaltrials.gov/study/NCT06884293) | A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | ACTIVE_NOT_RECRUITING | 479 |
| [NCT03325387](https://clinicaltrials.gov/study/NCT03325387) | A Study of Multiple Doses of LY3305677 in Healthy Participants | Healthy | Phase 1 | COMPLETED | 56 |
| [NCT05793450](https://clinicaltrials.gov/study/NCT05793450) | Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment | Renal Impairment | Phase 1 | COMPLETED | 20 |
| [NCT04965506](https://clinicaltrials.gov/study/NCT04965506) | A Study of IBI362 in Chinese Patients With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 252 |

## Common questions

**How many human trials does Mazdutide have?**
37, each listed above with a link to its original record.

**Is Mazdutide FDA approved?**
No. It is not approved by the FDA for any indication.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/mazdutide*